Introduction
A significant contributor to head and neck cancer morbidity and mortality are nasopharyngeal carcinomas (NPCs). Despite substantial breakthroughs in diagnostic imaging and mass screening approaches, 70–75% of all patients are identified with a locally advanced NPC (LA-NPC), presumably owing to the unique location and concealed nature of the disease [
1,
2]. Because it significantly improves locoregional disease control and survival, definitive platinum-based concurrent chemoradiotherapy (C-CRT) has replaced radiation alone or sequential chemoradiotherapy regimens in these patients [
3,
4]. Sadly, these advantages came at the expense of a marked rise in severe late complications, including radiation-induced trismus (RIT) and osteoradionecrosis of the jaw (ORNJ) in a sizeable percentage of patients.
Although RIT and ORNJ rates are decreasing owing to the advent of intensity-modulated radiation therapy (IMRT), they remain medical challenges to surmount because of their negative impacts on practically all patient-related quality of life (QOL) metrics [
5‐
7]. The prevalence of RIT (5-65%) and ORNJ (4-20%) varies significantly depending on the tumor location, tumor extension to the masticatory apparatus or jaw, treatment-related variables, and definitions utilized [
8,
9]. The traditional patient-, disease-, and treatment-related risk factors for RIT and ORNJ are commonly cited [
10,
11], but the patient’s biological condition and accompanying biomarkers are generally overlooked. However, Somay et al. and Yilmaz et al. recently discovered that high pretreatment systemic immune-inflammation index (SII) values were associated with decreased short-term success after temporomandibular joint (TMJ) arthrocentesis and an increased need for tooth extractions after C-CRT, respectively [
12,
13]. Moreover, Somay et al. recently reported that a low baseline hemoglobin-to-platelet ratio (HPR) in LA-NPC patients and a high neutrophil-to-lymphocyte ratio (NLR) in parotid gland cancer patients were significant predictors of RIT after C-CRT and RT, respectively [
14,
15]. All these recent findings suggest the possibility of using biological markers that reflect a patient’s overall immunological and inflammatory status as reliable indicators of treatment efficacy and late toxicity rates.
Another recently discovered biological marker is the host index (H-Index), which was first investigated in oral cavity squamous cell carcinomas treated with primary surgery by Valero et al. in 2020 [
16]. This novel comprehensive index was created by combining the routine neutrophil, monocyte, and lymphocyte counts as well as albumin and hemoglobin (Hb) levels from complete blood count and biochemistry tests. The findings of this study showed that patients with H-Index scores of 1.5 to 3.5 [hazard ratio (HR): 1.47] and 3.6 or higher (HR: 3.22) had a higher risk of death when compared to patients with an H-Index score of 1.4 or less. Later, these findings were validated for laryngeal, oropharyngeal, and hypopharyngeal cancer primaries, regardless of the extent of the disease or the type of therapy employed [
17,
18]. Unfortunately, NPC patients were not included in these studies, and the common endpoint was survival results, and neither study examined the H-Index’s potential value in predicting treatment-related toxicities like the RIT and ORNJ.
Persistent systemic inflammation, the seventh hallmark of cancer [
19], has been demonstrated to increase neutrophil, monocyte, and thrombocyte counts while decreasing lymphocyte levels [
20,
21]. Albumin levels fall in hyper-inflammatory circumstances because C-reactive protein inhibits albumin production in hepatocytes [
22]. Poor diet, which is frequent in cancer patients, may also cause low albumin levels [
23]. Anemia or low Hb levels, indicators of tissue hypoxia, are also ubiquitously encountered in cancer patients, including those with LA-NPC [
24]. Given the importance of these variables and associated cytokines in RIT and ORNJ genesis by inducing a favorable immune and inflammatory milieu, tissue hypoxia, vascular occlusion, and fibrotic tissue repair [
25,
26], we hypothesized that the H-Index could reliably predict the risk of severe late toxicities in LA-NPC patients. Motivated by the accessible fundamental grounds, we planned to examine the novel H-Index for its utility in predicting the RIT and ORNJ in LA-NPC patients treated with definitive C-CRT.
Discussion
The H-Index was tested for its ability to predict RIT and ORNJ rates in conclusively treated LA-NPC patients. In addition to confirming conventional risk factors, our findings showed that the ROC curve analysis-derived 5.5 cutoff value and the 3.5 cutoff value proposed by Valero and colleagues were both efficient in independently classifying these patients into two distinct risk groups for RIT and ORNJ rates [
16]. SWL during C-CRT was shown to be an additional independent predictor of greater RIT and ORNJ rates in our study. If confirmed by further research, these findings support the hypothesis that baseline quantities of immune cells, their secretory products, hypoxia, and nutritional state all play crucial roles in the genesis and advance of severe radiation-induced late toxicities.
In our study, 46 (15.6%) patients were diagnosed with RIT and 23 (7.8%) with ORNJ after C-CRT, which is consistent with the associated literature. The reported trismus rate in the MD Anderson Head and Neck Cancer Symptom Working Group study published in 2020, for example, was 29% [
32]. Even though the 7.8% ORNJ rate presented here appears to be slightly higher than the < 5% references, it is compatible with earlier IMRT studies. ORNJ rates in two IMRT trials reported by Tsai et al. [
33] and Maesschalck et al. [
34] were 6.0% and 10.2%, respectively. Numerous conventional disease-, patient-, and dosimetry-related factors have been linked to increased RIT and ORNJ rates in various head and neck tumors treated with RT or C-CRT, including LA-NPC [
35,
36]. These factors include tumors of the oral cavity and oropharynx, larger tumor sizes, higher T- and N stages, larger tumor sizes, previous surgery, the proximity of the primary tumor or involved lymph nodes to the masticatory apparatus and mandible, dental extractions before or after treatment, the presence of TMJ disorders, the use of concurrent chemotherapy, higher prescribed tumor doses, higher mean or median doses to the masticatory apparatus and mandible, and larger volumes of the masticatory muscles, joints, or mandibular bone receiving doses above a specified dose level [
35,
36]. In this regard, the current multivariate results confirmed the independent predictive significance of a pre-C-CRT MMO of ≤ 41.2 mm and a mean MAD dose of ≥ 48.5 Gy for higher RIT (P 0.05 for each) and the presence of smoking history, post-C-CRT dental extractions, an MMD of ≥ 36.2 Gy, and a mandibular V59 Gy of ≥ 32% (P 0.05 for each) for higher ORNJ rates.
Our study’s first notable discovery was the demonstration of a significant relationship between SWL during C-CRT and a higher rate of RIT (25.9% vs. 9.3%; HR: 2.76; P = 0.002). Before or during C-CRT, patients with LA-NPC may exhibit SWL and nutritional deficiencies, which is a recognized prognostic indicator for these patients [
37,
38]. Shen et al. [
37] and Zeng et al. [
38] found that any WL above the SWL thresholds of 5% and 4.6% was associated with significantly lower disease-free-, locoregional progression-free-, and overall survival rates in 2,433 and 606 curatively treated NPC patients, respectively, even after IMRT. Although RIT is often reported as one of the major causes of SWL in patients with head and neck cancer [
39], SWL has never been investigated as a cause of RIT. Despite the complex link between RIT and SWL, our findings are credible since 29 (25.9%) of 112 SWL patients and only 17 (9.3%) of 183 non-SWL patients exhibited RIT following C-CRT (P = 0.001). SWL during C-CRT may also be a sign of weakened immunity, persistent inflammation, cancer development, and/or related pre-cachexia or cachexia, all of which may contribute to RIT besides serving as prognostic factors in such patients. This logical consequence is relevant considering the critical roles performed by inappropriate immunity, persistent inflammation, cachexia-related muscle loss, and enhanced fibrotic repair processes in all components of the masticatory apparatus during RIT pathogenesis [
25].
In addition to its previously demonstrated utility in prognostic stratification of the oral cavity, oropharynx, hypopharynx, and larynx cancers [
16‐
18], we established a first for LA-NPC literature by showing that the risk for (31.8% vs. 5.9% for H-Index < 5.5; P < 0.001) and ORNJ (17.3% vs. 2.2% for H-Index < 5.5) after C-CRT rises with increasing H-Index value. The H-Index potentially offers a host-related biomarker for categorizing survival outcomes or toxicity rates after a given oncological therapy by integrating immunological, inflammatory, nutritional, and oxygenation status surrogates like albumin and Hb. Although we were unable to demonstrate a significant utility for H-Index in terms of its predictive capabilities for three distinct RIT and ORNJ groups using Valero’s 1.5 and 3.5 cutoffs [
16], we confirmed that the 3.5 cutoff was successfully able to stratify these patients into two significantly different groups concerning RIT (23.6% vs. 0.96% for H-Index < 3.5; P < 0.001) and ORNJ (10.5% vs. 2.9% for H-Index < 3.5; P < 0.001). Further, we clinched that 5.5 was the ideal H-Index cutoff in ROC curve analysis to divide these patients into two groups with significantly different risks for RIT (31.8 vs. 5.9% for H-Index < 5.5; P < 0.001) and ORNJ (17.3 vs. 2.2% for H-Index < 5.5; P < 0.001) after definitive C-CRT. Although the specific cause of this cutoff variation is unknown, it might be attributable to variances in the endpoints, tumor locales, tumor stages, and treatment modalities used here and elsewhere [
16‐
18]. Further substantiating the relevance of this statement, an H-Index of 8.37 was found to be the ideal cut-off to distinguish the group of surgically treated laryngeal cancer patients with a higher risk of both recurrence/death (HR: 2.82) and only death (HR: 2.22) in the study reported by Boscolo-Rizzo et al. [
17].
The exact pathophysiological mechanisms underlying the association between a high pre-C-CRT H-Index and noticeably elevated RIT and ORNJ rates remain unknown. However, valuing the distinct immune and inflammatory functions of neutrophils, monocytes, and lymphocytes, as well as the crucial roles of Hb and albumin in tissue oxygenation and nutritional status, it might be possible to formulate some insightful remarks. Reduced peripheral lymphocyte counts insinuate a severely compromised immune response and intensified chronic systemic inflammation [
40]. The production and activation of inflammatory chemokines and cytokines are heavily dependent on neutrophil and monocyte counts [
41]. These cells may also inhibit T-cell activation and proliferation, thereby suppressing immune responses and exacerbating ongoing systemic inflammation [
41]. The systemic inflammation response index (SIRI) is created by combining the three cellular elements of the H-Index. So, the H-Index can also be expressed as H-Index = [SIRI ÷ (Hb × Albumin)
−1] × 100. Despite SIRI’s well-established prognostic value in patients with LA-NPC [
42], there hasn’t been any prior research linking radiation-induced toxicity and pretreatment levels in LA-NPC or other head and neck cancers. However, Somay et al. recently showed that the SII, a variant of SIRI where only the monocytes are replaced by platelets in the formula, was related to worse TMJ arthrocentesis results [
12]. Two more investigations by Somay et al. found that parotid gland cancer and LA-NPC patients with a high pre-radiotherapy neutrophil-to-lymphocyte ratio (NLR), a factor of the H-Index, and a low HPR had vastly higher rates of RIT [
14,
15]. These data clearly show that elevated blood-borne cellular marker concentrations increase RIT occurrence and reduce treatment effectiveness after TMJ arthrocentesis.
Albumin and Hb are the non-cellular components of the H-Index formula. There is a universal consensus that damaged tissues need increased oxygenation [
43], hence, low Hb levels may function as a systemic indirect surrogate signal for tissue hypoxia and poor tissue repair, such as the RIT and ORNJ. Marx’s hypoxic-hypocellular-hypovascular hypothesis of ORNJ lends some credence to this assertion [
44]. According to this hypothesis, following radiation exposure, hypoxic, hypovascular, and hypocellular tissue develops, followed by a chronic, non-healing necrotic process caused by persistent hypoxia. By elevating TGF-beta, VEGF, and CD-31 (an endothelial cell marker), radiation-induced hypoxia may worsen an already existing hypoxic state and accelerate late tissue harm [
45]. This finding suggests that the fibrinogenic and angiogenic pathways are crucial in radiation-induced late tissue injuries like the RIT and ORNJ. According to fibroatrophic theory, RIT and ORNJ may be caused by TMJ, mandibular elevator muscle, and jaw fibrosis [
46,
47]. Cancer patients often have hyper-catabolic, hyper-inflammatory, and malnourished states, which can inhibit albumin synthesis via elevated C-reactive protein [
22,
23]. Thus, low albumin levels may indicate poor immunity, chronic inflammation, nutritional status, and muscle mass loss in such patients, including masticatory and vascular muscle layers. These data offer a strong foundation for the elevated risk of RIT and ORNJ in LA-NPC patients with a high H-Index, as observed here, even though the precise mechanism is probably more complex.
Biomarkers Definitions Working Group defines a biomarker as a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention [
48]. The following characteristics should be present in an ideal clinical biomarker according to Lesko and Atkinson [
49]: [
1] clinical relevance, [
2] high sensitivity and specificity, [
3] reliability, [
4] practicality, and [
5] simplicity. An ideal biomarker should also be replicable, simple to achieve and perform, and affordable enough to be widely adopted. Given these features and the consistent findings from H-Index studies and those presented here, the H-Index appears to be an excellent biomarker for predicting survival outcomes and severe late toxicities in LA-NPC patients.
The present study is strengthened by several factors. First, head and neck MRI and PET-CT were the standard initial staging procedures for all qualified patients to improve NPC staging, target volume delineation, and response and toxicity assessments. Second, the unexpected biasing effect of disease and treatment variables may have been reduced because all patients had a comparable disease stage and underwent a standard oral examination and C-CRT protocol. Third, all patients had their H-Index constituents measured on the first day of C-CRT, which may have mitigated the effects of time-dependent parameter variations. However, this study has some drawbacks. First, since the results presented here would have been unintentionally biased in favor of one group by some unforeseen factors, a problem bedeviling all retrospectively designed single-institutional investigations, they should only be considered hypothesis-generating. Second, the H-Index cutoffs used here and their effects on the results reflect only a single time-point estimation and related RIT and ORNJ rates that skip the fluctuating nature of the measures of the H-Index constituents. Thus, future comprehensive research on H-Index dynamics may provide more dedicated cutoff(s) for more accurate RIT and ORNJ rate prediction. And third, without the H-Index and cytokine/chemokine correlations, we may have missed the chance to assess and offer insights into possible mechanistic links between the H-Index and other nutritional and immune-inflammatory factors.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.